Phase II Trial Shows Promise for Probiotic BL21 in Preventing Radiation-Induced Enteritis
Key Insights
A phase II clinical trial of Bifidobacterium longum subsp. longum BL21 (search) demonstrated favorable safety and reduced severity of acute radiation enteritis in cancer patients receiving pelvic radiotherapy.
The study enrolled 52 patients with gynecologic or rectal cancers, with 44 completing the analysis, showing lower rates of grade 2 or higher enteritis compared to historical controls.
Gut microbiota analysis revealed that BL21 (search) abundance correlated with reduced enteritis severity and was associated with increased beneficial bacteria and greater microbial diversity.
A phase II clinical trial has demonstrated the potential of Bifidobacterium longum subsp. longum BL21 (search) (BL21 (search)) as a prophylactic treatment for acute radiation enteritis (ARE), a common and debilitating side effect experienced by cancer patients undergoing pelvic radiotherapy. The study, conducted across multiple medical centers in China, showed promising safety and efficacy signals that warrant further investigation in larger randomized trials.
Study Design and Patient Population
The single-arm phase II trial recruited patients with gynecologic or rectal cancers who were scheduled to receive pelvic radiotherapy with curative or adjuvant intent. Of the 52 patients initially enrolled, 44 completed the study and were included in the final analysis after 8 participants withdrew. During their radiotherapy treatment, patients self-administered one packet of BL21 (search) powder daily.
The study assessed ARE using established toxicity grading criteria from both the Radiation Therapy Oncology Group (RTOG) and Common Terminology Criteria for Adverse Events (CTCAE). Researchers evaluated both the safety profile of BL21 (search) and its efficacy in preventing ARE while investigating changes in the intestinal microbiota.
Safety and Clinical Outcomes
The trial demonstrated a favorable safety profile for BL21 (search) during radiotherapy, with no serious adverse events associated with the probiotic intervention observed throughout the study period. When compared to historical control data, patients receiving BL21 exhibited notably lower levels of grade 2 or higher ARE.
The clinical benefits were particularly evident in the reduced need for antidiarrheal medications, with only 12 patients requiring such interventions. Most diarrhea cases that did occur were classified as grade 1 severity, with 22 patients experiencing this milder form of the condition.
Microbiome Analysis Reveals Mechanistic Insights
Analysis of the gut microbiota provided valuable insights into the mechanism underlying BL21 (search)'s protective effects. The research revealed a clear correlation between the severity of ARE and the abundance of BL21 in the intestinal tract. Patients with higher BL21 levels experienced less severe enteritis symptoms.
The microbiome analysis further demonstrated that increased BL21 (search) abundance was associated with greater alpha diversity, indicating a more robust and balanced gut microbial ecosystem. Additionally, BL21 supplementation led to an increase in beneficial bacteria while simultaneously reducing harmful bacterial populations.
Clinical Implications and Future Directions
The study's findings position BL21 (search) as a promising prophylactic candidate for preventing ARE in cancer patients undergoing pelvic radiotherapy. The combination of favorable safety profile, exploratory clinical observations showing reduced ARE severity compared to historical controls, and the feasible administration method supports the advancement of this intervention to more definitive testing.
The researchers concluded that these positive results warrant validation in Phase III randomized controlled trials, which would provide the robust evidence needed to establish BL21 (search) as a standard prophylactic treatment for radiation-induced enteritis. Such trials would be essential for confirming the efficacy signals observed in this phase II study and could potentially transform supportive care for cancer patients receiving pelvic radiotherapy.